Ipamorelin vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
IpamorelinAnti-Aging & Longevity
Chonluten- Summary
- Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- 2 hours
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 10 mg per day
- Frequency
- Once to twice daily
- Daily for 10–30 days
- Key Benefits
- Increases lean muscle mass
- Enhances fat loss
- Improves recovery time
- Strengthens bones and joints
- Better sleep quality and REM sleep
- Enhanced skin elasticity
- Minimal impact on hunger or cortisol
- No cortisol or prolactin spike
- Clean GH release suitable for long-term protocols
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Injection site irritation
- Temporary water retention (mild)
- Possible hunger increase (milder than GHRP-6)
- Numbness or tingling in extremities (rare)
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —